Acorda Therapeutics Inc (ACORQ)
0.605
+0.10
(+18.63%)
USD |
OTCM |
May 17, 16:00
Acorda Therapeutics Research and Development Expense (Quarterly): 0.954M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.954M |
| December 31, 2023 | 1.009M |
| September 30, 2023 | 1.207M |
| June 30, 2023 | 1.55M |
| March 31, 2023 | 1.386M |
| December 31, 2022 | 1.202M |
| September 30, 2022 | 1.383M |
| June 30, 2022 | 1.525M |
| March 31, 2022 | 1.694M |
| December 31, 2021 | 1.366M |
| September 30, 2021 | 1.931M |
| June 30, 2021 | 2.374M |
| March 31, 2021 | 4.749M |
| December 31, 2020 | 4.323M |
| September 30, 2020 | 5.729M |
| June 30, 2020 | 5.255M |
| March 31, 2020 | 7.705M |
| December 31, 2019 | 9.023M |
| September 30, 2019 | 16.07M |
| June 30, 2019 | 18.96M |
| March 31, 2019 | 16.03M |
| December 31, 2018 | 27.06M |
| September 30, 2018 | 22.86M |
| June 30, 2018 | 25.91M |
| March 31, 2018 | 30.56M |
| Date | Value |
|---|---|
| December 31, 2017 | 35.14M |
| September 30, 2017 | 33.29M |
| June 30, 2017 | 51.18M |
| March 31, 2017 | 46.49M |
| December 31, 2016 | 53.80M |
| September 30, 2016 | 54.78M |
| June 30, 2016 | 50.29M |
| March 31, 2016 | 44.57M |
| December 31, 2015 | 43.99M |
| September 30, 2015 | 43.36M |
| June 30, 2015 | 31.23M |
| March 31, 2015 | 30.64M |
| December 31, 2014 | 25.92M |
| September 30, 2014 | 16.58M |
| June 30, 2014 | 16.45M |
| March 31, 2014 | 14.52M |
| December 31, 2013 | 14.30M |
| September 30, 2013 | 13.84M |
| June 30, 2013 | 13.22M |
| March 31, 2013 | 12.52M |
| December 31, 2012 | 18.19M |
| September 30, 2012 | 12.03M |
| June 30, 2012 | 12.63M |
| March 31, 2012 | 11.02M |
| December 31, 2011 | 10.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.954M
Minimum
Mar 2024
18.96M
Maximum
Jun 2019
4.470M
Average
1.812M
Median
Research and Development Expense (Quarterly) Benchmarks
| BioSig Technologies Inc | 1.176M |
| Verve Therapeutics Inc | 48.38M |
| Spectral AI Inc | -- |
| AIM ImmunoTech Inc | 3.20M |
| Protalix BioTherapeutics Inc | 2.887M |